A groundbreaking study involving cats infected with a deadly coronavirus has shed light on the potential of stem cell therapy in aiding recovery from severe COVID-19 and long COVID symptoms. Conducted by researchers at UC Davis, the study revealed that cats treated with mesenchymal stem cells alongside antiviral drugs exhibited enhanced immune recovery compared to those receiving antiviral treatment alone.
This research is significant as feline infectious peritonitis (FIP), the disease studied in cats, shares similarities with severe human coronavirus infections, triggering a ‘cytokine storm’ and immune depletion. The study, published in Stem Cells Translational Medicine, showcased how mesenchymal stem cells, known for their anti-inflammatory properties, played a crucial role in resetting the immune systems of the treated cats. By reducing signs of T-cell exhaustion and promoting the development of regulatory T-cells, the stem cell therapy demonstrated promising results. This blog post delves into the details of this groundbreaking study and its implications for potential stem cell therapies in the context of long COVID.
Read more from studyfinds.org